<DOC>
	<DOC>NCT02428894</DOC>
	<brief_summary>The purpose of this study is to characterize changes in the plasma proteome over time following left ventricular assist device (LVAD) implantation.</brief_summary>
	<brief_title>Characterization of the Plasma Proteome Following Left Ventricular Assist Device Implantation</brief_title>
	<detailed_description />
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction, Left</mesh_term>
	<criteria>Planned HeartMate II LVAD implantation Planned warfarin (goal INR, 2.03.0) and lowdose aspirin therapy postLVAD placement Prior history of mechanical circulatory support; Body weight &lt; 110 lbs; Preexisting hemolytic, bleeding, or immunologic disorders prior to LVAD implantation; Severe aortic stenosis; Renal failure requiring dialysis; Hepatic dysfunction resulting in severe coagulopathies; Recent serious infection; Current need for prolonged ventilatory support; Prior organ transplantation; Blood transfusion within 14 days of the first planned study blood draw; Concomitant immunosuppressant or chemotherapeutic agents; Pregnant women; Decisionally challenged or prisoners; Unwilling to provide written informed consent</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>